CMPS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CMPS is not a clear good buy right now for a Beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock has supportive long-term upside from pipeline/approval catalysts, but the current setup is better viewed as a speculative hold than an immediate buy because the recent price action is weak, the company is still loss-making, and the next major catalyst is earnings. If the investor is impatient and wants to enter now rather than wait, I would not call this a strong buy today; it is a hold until the next earnings/FDA-related confirmation gives better conviction.
Technically, CMPS is in a constructive medium-term trend but has short-term weakness. Price closed at 9.28 after a -3.79% regular-session drop and is below the prior close of 9.39. Still, the moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports an intact uptrend structure. MACD histogram is positive at 0.0741, but it is contracting, suggesting momentum is fading rather than accelerating. RSI_6 at 60.0 is neutral-to-mildly bullish, not overbought. Key levels: pivot 9.085, resistance 9.727/10.123, support 8.443/8.047. Overall, the trend is positive but currently losing steam.
Positive catalysts include Jefferies initiating Buy with an $18 target and high confidence in FDA approval for COMP360 in FY26, plus multiple other bullish analyst actions raising targets. The company has Breakthrough Therapy designation from the FDA and ILAP designation in the UK, which supports the regulatory story. News also highlights an upcoming Q1 earnings report and conference call, which can act as a near-term catalyst. Hedge funds are buying, with buying up 302.54% over the last quarter. The broader long-term catalyst remains potential first-to-market approval in treatment-resistant depression.
The biggest negatives are that the company is still deeply unprofitable and revenue remains 0, so financial fundamentals are not yet supportive of a long-term value thesis. The stock also fell sharply in the latest session and the one-month pattern estimate points to -2.18%, suggesting near-term weakness after the recent move. SwingMax and AI Stock Picker both show no active signal today, so there is no proprietary timing edge. Insider activity is neutral, and there is no recent congress trading data to add a bullish confirmation. The next earnings date is very close, so the stock may remain headline-driven rather than fundamentally de-risked.
Latest reported quarter: 2025/Q4. Revenue was 0, flat year over year, so there is no commercial revenue growth yet. Net income was -93.9 million, though improved 116.65% YoY, and EPS was -0.98, improved 55.56% YoY. That indicates loss reduction, but not profitability. For a long-term investor, the trend is improving on losses, but the business is still pre-revenue and highly dependent on regulatory progress.
Analyst sentiment is clearly bullish overall. Recent actions include Jefferies initiating Buy at $18, Oppenheimer Outperform at $20, B. Riley Buy at $17, and prior upgrades/raises from Canaccord, Stifel, Morgan Stanley, RBC, and LifeSci. The trend is toward higher confidence in approval and earlier launch timing for COMP360. Wall Street pros mostly see upside and a favorable FDA path, with the main pro being first-to-market approval potential and the main con being execution and commercialization risk before approval.
